Literature DB >> 17000724

Leishmania chagasi T-cell antigens identified through a double library screen.

Daniella R A Martins1, Selma M B Jeronimo, John E Donelson, Mary E Wilson.   

Abstract

Control of human visceral leishmaniasis in regions where it is endemic is hampered in part by limited accessibility to medical care and emerging drug resistance. There is no available protective vaccine. Leishmania spp. protozoa express multiple antigens recognized by the vertebrate immune system. Since there is not one immunodominant epitope recognized by most hosts, strategies must be developed to optimize selection of antigens for prevention and immunodiagnosis. For this reason, we generated a cDNA library from the intracellular amastigote form of Leishmania chagasi, the cause of South American visceral leishmaniasis. We employed a two-step expression screen of the library to systematically identify T-cell antigens and T-dependent B-cell antigens. The first step was aimed at identifying the largest possible number of clones producing an epitope-containing polypeptide by screening with a pool of sera from Brazilians with documented visceral leishmaniasis. After removal of clones encoding heat shock proteins, positive clones underwent a second-step screen for their ability to cause proliferation and gamma interferon responses in T cells from immune mice. Six unique clones were selected from the second screen for further analysis. The corresponding antigens were derived from glutamine synthetase, a transitional endoplasmic reticulum ATPase, elongation factor 1gamma, kinesin K39, repetitive protein A2, and a hypothetical conserved protein. Humans naturally infected with L. chagasi mounted both cellular and antibody responses to these proteins. Preparations containing multiple antigens may be optimal for immunodiagnosis and protective vaccines.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17000724      PMCID: PMC1698060          DOI: 10.1128/IAI.02032-05

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  57 in total

Review 1.  The strange case of Leishmania chagasi.

Authors:  I L Maurício; J R Stothard; M A Miles
Journal:  Parasitol Today       Date:  2000-05

2.  Therapy of murine cutaneous leishmaniasis by DNA vaccination.

Authors:  E Handman; A H Noormohammadi; J M Curtis; T Baldwin; A Sjölander
Journal:  Vaccine       Date:  2000-07-01       Impact factor: 3.641

Review 3.  Clinical spectrum of Leishmaniasis.

Authors:  R D Pearson; A Q Sousa
Journal:  Clin Infect Dis       Date:  1996-01       Impact factor: 9.079

4.  The developmental expression of Leishmania donovani A2 amastigote-specific genes is post-transcriptionally mediated and involves elements located in the 3'-untranslated region.

Authors:  H Charest; W W Zhang; G Matlashewski
Journal:  J Biol Chem       Date:  1996-07-19       Impact factor: 5.157

5.  Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis.

Authors:  L Soong; S M Duboise; P Kima; D McMahon-Pratt
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

6.  Molecular evidence for the importation of Old World Leishmania into the Americas.

Authors:  H Momen; R S Pacheco; E Cupolillo; G Grimaldi Júnior
Journal:  Biol Res       Date:  1993       Impact factor: 5.612

7.  Identification and overexpression of the A2 amastigote-specific protein in Leishmania donovani.

Authors:  W W Zhang; H Charest; E Ghedin; G Matlashewski
Journal:  Mol Biochem Parasitol       Date:  1996-06       Impact factor: 1.759

8.  Response of Leishmania chagasi promastigotes to oxidant stress.

Authors:  M E Wilson; K A Andersen; B E Britigan
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

9.  A recombinant Leishmania chagasi antigen that stimulates cellular immune responses in infected mice.

Authors:  M E Wilson; B M Young; K P Andersen; J V Weinstock; A Metwali; K M Ali; J E Donelson
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

10.  Cloning and expression of a Leishmania donovani gene instructed by a peptide isolated from major histocompatibility complex class II molecules of infected macrophages.

Authors:  A Campos-Neto; L Soong; J L Cordova; D Sant'Angelo; Y A Skeiky; N H Ruddle; S G Reed; C Janeway; D McMahon-Pratt
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

View more
  7 in total

1.  Mitigating an undesirable immune response of inherent susceptibility to cutaneous leishmaniosis in a mouse model: the role of the pathoantigenic HISA70 DNA vaccine.

Authors:  Gustavo Domínguez-Bernal; Pilar Horcajo; José A Orden; Ricardo De La Fuente; Aldara Herrero-Gil; Lara Ordóñez-Gutiérrez; Javier Carrión
Journal:  Vet Res       Date:  2012-08-09       Impact factor: 3.683

2.  The Leishmania HSP20 is antigenic during natural infections, but, as DNA vaccine, it does not protect BALB/c mice against experimental L. amazonensis infection.

Authors:  Ana M Montalvo-Alvarez; Cristina Folgueira; Javier Carrión; Lianet Monzote-Fidalgo; Carmen Cañavate; Jose M Requena
Journal:  J Biomed Biotechnol       Date:  2008

3.  New Vaccine Formulations Containing a Modified Version of the Amastigote 2 Antigen and the Non-Virulent Trypanosoma cruzi CL-14 Strain Are Highly Antigenic and Protective against Leishmania infantum Challenge.

Authors:  Ana Paula M M Almeida; Leopoldo F M Machado; Daniel Doro; Frederico C Nascimento; Leonardo Damasceno; Ricardo Tostes Gazzinelli; Ana Paula Fernandes; Caroline Junqueira
Journal:  Front Immunol       Date:  2018-03-15       Impact factor: 7.561

4.  Deletion of Glutamine Synthetase Gene Disrupts the Survivability and Infectivity of Leishmania donovani.

Authors:  Vinay Kumar; Sanhita Ghosh; Kamalika Roy; Chiranjib Pal; Sushma Singh
Journal:  Front Cell Infect Microbiol       Date:  2021-02-26       Impact factor: 5.293

5.  Identification of novel Leishmania donovani antigens that help define correlates of vaccine-mediated protection in visceral leishmaniasis.

Authors:  Sudipta Bhowmick; Nahid Ali
Journal:  PLoS One       Date:  2009-06-05       Impact factor: 3.240

6.  Influence of culture medium on the production of eif antigen from Leishmania chagasi in recombinant Escherichia coli.

Authors:  Michelle Rossana Ferreira Vaz; Ricardo Luiz Soares de França; Sirtys Santos Lessa de Andrade; Francisco Canindé de Sousa Junior; Everaldo Silvino Dos Santos; Daniella Regina Arantes Martins; Gorete Ribeiro de Macedo
Journal:  Braz J Microbiol       Date:  2011-12-01       Impact factor: 2.476

7.  Identification of differentially expressed proteins from Leishmania amazonensis associated with the loss of virulence of the parasites.

Authors:  Rubens D M Magalhães; Mariana C Duarte; Eliciane C Mattos; Vivian T Martins; Paula S Lage; Miguel A Chávez-Fumagalli; Daniela P Lage; Daniel Menezes-Souza; Wiliam C B Régis; Maria J Manso Alves; Manuel Soto; Carlos A P Tavares; Ronaldo A P Nagen; Eduardo A F Coelho
Journal:  PLoS Negl Trop Dis       Date:  2014-04-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.